Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — FY2020 Earnings Presentation

21 slides from Jcr Pharmaceuticals's earnings presentation, May 17, 2021

  1. Slide 1: FY2020 Results Briefing Session

    FY2020 Results Briefing Session Financial Results -Fiscal Year 2020- May 17, 2021 JCR Pharmaceuticals co., Ltd. 【Securities code】 4552, 1st Sec. TSE Copyright © 2021 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  2. Slide 2: Financial Highlights (FY2020 results)

    Financial Highlights (FY2020 results) Net sales, operating income, ordinary income and profit have all reached record highs Net sales：30,085million yen, Year-on-year +21.4％ Operating Income：8,269million yen, YoY +154.9％ Ordinary Income：8,488million yen, YoY +157.7％ Profit : 6,892million yen, YoY +15

  3. Slide 3: Consolidated Results

    Consolidated Results (Unit: million yen) FY2019 FY 2020 Reference (Apr. 1, 2019- (Apr. 1, 2020-Mar. 31, 2021) Consolidated Mar. 31, 2020) Year-on-Year Initial forecast A B (B-A)/A (before fixing) Net sales 24,781 30,085 +21.4% 27,200 Cost of Sales 7,901 7,812 (1.1)% 6,800 Gross Profit 16,880 22,272

  4. Slide 4: Breakdown of net sales

    Breakdown of net sales (Consolidated) (Unit: million yen) FY2019 FY2020 (Apr. 1, 2019- Mar. 31, 2020) (Apr. 1, 2020- Mar. 31, 2021) Composition Composition Year-on-Year Ａ ratio Ｂ ratio (B-A)/A GROWJECT® 12,650 51.0% 13,256 44.1% +4.8% Treatments for renal anemia 5,509 22.2% 7,087 23.6% +28.6% Epoeti

  5. Slide 5: Balance Sheet

    Balance Sheet (Consolidated) (Unit: million yen) Mar. Mar. Main Mar. Mar. Main 2020 2021 Increase/decrease 2020 2021 Increase/decrease Short-term loans payable ＋7,970 Cash and deposits Current Special suspense ＋15,287 10,434 29,028 Accounts liabilities account for tax Current purpose reduction 28,34

  6. Slide 6: Cash Flows

    Cash Flows (Consolidated) (Unit: million yen) 営業活動によるCF Operating Activities End of End of Year-on-year 投資活動によるCF Investing Activities Mar. 2020 Mar. 2021 Ｂ-Ａ Ａ Ｂ 財務活動によるCF Financing Activities Income before income 期末 Cash 現金及び現金同等物 and Cash Equivalents at End of Period 3,422 8,653 5,231 taxes Depre

  7. Slide 7: Forecast Highlights (FY2021)

    Forecast Highlights (FY2021) Net sales：49,000million yen, Year-on-year + 62.9% Operating income：18,700million yen, YoY +126.1% Ordinary income ：18,700million yen, YoY +120.3% Profit：13,300million yen, YoY +92.9% ■ Topics of core products: The launch of the IZCARGO® and growth in sales volume of GROW

  8. Slide 8: FY2021 Forecast

    FY2021 Forecast (Consolidated) (Unit: million yen) FY2020 FY2021 forecast Increase/ (Apr. 1, 2020- (Apr. 1, 2021- Year-on-Year Consolidated decrease Mar. 31, 2021) Mar. 31, 2022) (B-A)/A A B Ｂ-Ａ Net Sales 30,085 49,000 +18,915 +62.9% Cost of sales 7,812 8,300 +488 +6.2% Gross profit 22,272 40,700 +1

  9. Slide 9: FY2021 Forecast by product

    FY2021 Forecast (Consolidated) (Unit: million yen) FY2020 FY2021 forecast Increase/ Name of Business (Apr. 1, 2020-Mar. 31, 2021) (Apr. 1, 2021-Mar. 31, 2022) decrease segment Composition Composition (B-A) Ａ ratio Ｂ ratio GROWJECT® 13,256 44.1% 13,900 28.4% +644 Treatments for renal anemia 7,087 23.

  10. Slide 10: Forward-Looking Statement

    FORWARD- LOOKING STATEMENT This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward-looking statements regarding our plans, outlook, strategy and future performance are based on judgments derived

  11. Slide 11: Copyright © 2021 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2021 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  12. Slide 12: Reference: Year-on-year changes (Consolidated)

    Reference：Year-on-year changes (Conoslidated) (Unit: million yen) ◆ Net Sales 30,085million yen, Year-on-Year +5,304million yen Factors of change FY2019 24,781 • At this point in time, the JCR Group has not GROWJECT +605 felt the impact of the COVID-19 pandemic. Epoetin Alpha BS (819) • GROWJECT Dar

  13. Slide 13: Reference: Trend in Sales by Business Segments

    Reference: Trend in Sales by Business Segments (Consolidated) (Unit: million yen) 11 6,396 1,051 Other 773 404 License Revenue 250 1,048 7 AZD1222 bulk 74 194 10 1,656 2,506 220 Agalsidase Beta BS 1,002 1,599 784 274 219 123 TEMCELL 1,027 1,054 74 Darbepoetin Alpha BS 1,527 2,114 1,625 512 1,052 1,4

  14. Slide 14: Reference: Trend in Balance Sheets

    Reference: Trend in Balance Sheets (Consolidated) (Unit: million yen) Assets Liabilites and net assets Current assets Property, plant and equipment Current liabilities Non-current liabilities Intangible assets Investments and other assets Total net assets Equity ratio 70.3% 71.1% 4,833 66.6% 3,232 3

  15. Slide 15: Reference: Trend in Cash Flows

    Reference: Trend in Cash Flows (Consolidated) (Unit: million yen) FY2017 FY2017 FY2018 FY2018 FY2019 FY2019 FY2020 FY2020 1stH 2ndH 1stH 2ndH 1stH 2ndH 1stH 2ndH Operating Activities 1,830 1,830 1,303 1,303 2,372 2,372 1,533 1,533 2,949 2,949 1,978 1,978 4,232 4,232 6,109 6,109 Investing Activities

  16. Slide 16: Reference: Trend in Gross Profit margin

    Reference: Trend in Gross Profit margin (except AZD1222 bulk) (Unit: million yen) Products* sales License Revenue Gross profit margin (Products* sales) Gross profit margin (including License Revenue) *Products：GROWJECT, Treatment for renal anemia, TEMCELL, Agalsidase beta BS, Other 77.1% 73.7% 72.3%

  17. Slide 17: Reference: Trend in composition ratio of cost/expense

    Reference: Trend in composition ratio of cost/expense Operating Income R&D Expenses SG&A Cost of Sales 26.0% 29.8% 28.4% 31.9% 6,567 7,812 6,128 7,901 28.7％ 31.4% 31.4% 8,643 30.8% Above number (％) 6,469 7,270 7,638 rate of sales Below number (Million yen) 17.8％ Amount of money 18.8% 5,360 20.5% 4,3

  18. Slide 18: Reference: Correlation between R&D expenses and main R&D pipeline

    Reference: Correlation between R&D expenses and main R&D pipeline (Unit: million yen) R&D Expenses (before deducting) Preclinical Clinical trial Filed an application 11,080 Approved 6,582 4,865 5,270 5,856 FY2017 FY2018 FY2019 FY2020 FY2021(Forecast) JR-141 (Japan) JR-141 (Brazil) JR-141 (Global) JR

  19. Slide 19: Reference: Midterm Business Plan for 2020-2022

    Reference: Midterm Business Plan for 2020-2022 Top priority business challenge in anticipation of growing presence of JCR in the rare disease area [1] Qualitative and quantitative reorganization of the quality assurance system For strengthening our foundation for profits: [2] Action for sustainable

  20. Slide 20: Reference: Guidance

    Reference: Guidance Achievements Achievements in Forecast in Goals for FY2022 in FY2019 FY2020 FY2021 ¥32.0-36.0 Net sales ¥24.7 billion ¥30.0 billion ¥49.0 billion billion Operating ¥7.0～10.0 income ¥3.2 billion ¥8.2 billion ¥18.7 billion billion R&D Around 20％ of expenditures 24.2％ 17.82％ 21.02％ R

  21. Slide 21: Reference: IZCARGO Indications Mucopolysaccharidosis II

    Reference: IZCARGOⓇ First-ever Enzyme Replacement Treatment that penetrates the Blood-Brain-barrier via intravenous administration in Japan International Nonproprietary name: pabinafusp alfa MHLW Orphan Drug Designation Indications Mucopolysaccharidosis II Approval date in Japan March 23, 2021 Numbe

JCR Pharmaceuticals — FY2020 Earnings Presentation on 6ix